Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2017 Financial Results

Keryx Biopharmaceuticals (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with kidney disease, today announced its financial results for the fourth quarter and year ended December 31, 2017.

As quoted in the press release:

“In 2017, we brought Auryxia to an increasing number of people with hyperphosphatemia, and with the recent approval of a second indication, we are confident we can bring Auryxia to even more patients living with chronic kidney disease in the coming years,” said Greg Madison, president and chief executive officer of Keryx Biopharmaceuticals.

Click here to read the full press release.